ASSIMILATING THE EVIDENCE IN T2DM: Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Wed, Jul 15, 2020
at 3:00 PM
ABOUT THIS WEBINAR
This CME-accredited Case-in-Point™ webinar is designed to address the needs of endocrinologists and other diabetes specialists. Drs. Daniel Einhorn, Serge A. Jabbour, Marc S. Sabatine, and Kumar Sharma will guide participants through a series of representative clinical case scenarios to ensure learners understand the pathophysiologic link between type 2 diabetes mellitus (T2DM) and common comorbidities like cardiovascular disease, chronic kidney disease, and heart failure. Faculty will also detail recently revised guidelines, updated trial data, and appropriate therapeutic selection, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, for patients with T2DM and common comorbidities.
The educational design of this series addresses the needs of endocrinologists and other diabetes specialists.
Upon completion of this activity, participants should be better able to:
• Explain the pathophysiologic relationships between T2DM and cardiovascular disease, heart failure, and chronic kidney disease, including implications for treatment
• Compare the designs and results of large-scale renal and cardiovascular outcomes trials with SGLT2 inhibitors for T2DM
• Describe multidimensional efficacy and safety profiles and prescribing considerations for SGLT2 inhibitors in patients with T2DM
• Incorporate common comorbidities (eg, cardiovascular disease, heart failure, and chronic kidney disease) into treatment planning for patients with T2DM
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
PIM designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
PIM requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
PIM CONTACT INFORMATION
For information about the accreditation of this program, please contact PIM via email at firstname.lastname@example.org
This activity is provided by Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from AstraZeneca.
Wednesday, July 15, 2020 at 3:00 PM
Eastern Time (US & Canada)
Who can attend?Anyone with the event link can attend
Chairman, TIMI Study Group
Director, Brigham Research Institute
Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School